Global Non-alcoholic Steatohepatitis Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.
LPI (LP Information)' newest research report, the “Non-alcoholic Steatohepatitis Industry Forecast” looks at past sales and reviews total world Non-alcoholic Steatohepatitis sales in 2022, providing a comprehensive analysis by region and market sector of projected Non-alcoholic Steatohepatitis sales for 2023 through 2029. With Non-alcoholic Steatohepatitis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-alcoholic Steatohepatitis industry.
This Insight Report provides a comprehensive analysis of the global Non-alcoholic Steatohepatitis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-alcoholic Steatohepatitis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Non-alcoholic Steatohepatitis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-alcoholic Steatohepatitis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-alcoholic Steatohepatitis.
The global Non-alcoholic Steatohepatitis market size is projected to grow from US$ 3115.9 million in 2022 to US$ 12070 million in 2029; it is expected to grow at a CAGR of 12070 from 2023 to 2029.
United States market for Non-alcoholic Steatohepatitis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Non-alcoholic Steatohepatitis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Non-alcoholic Steatohepatitis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Non-alcoholic Steatohepatitis players cover AstraZeneca, Arena Pharmaceuticals, GSK, Novo Nordisk, Roche, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals and Galectin Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-alcoholic Steatohepatitis market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Non-alcoholic Steatohepatitis market?
What factors are driving Non-alcoholic Steatohepatitis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non-alcoholic Steatohepatitis market opportunities vary by end market size?
How does Non-alcoholic Steatohepatitis break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.
LPI (LP Information)' newest research report, the “Non-alcoholic Steatohepatitis Industry Forecast” looks at past sales and reviews total world Non-alcoholic Steatohepatitis sales in 2022, providing a comprehensive analysis by region and market sector of projected Non-alcoholic Steatohepatitis sales for 2023 through 2029. With Non-alcoholic Steatohepatitis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-alcoholic Steatohepatitis industry.
This Insight Report provides a comprehensive analysis of the global Non-alcoholic Steatohepatitis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-alcoholic Steatohepatitis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Non-alcoholic Steatohepatitis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-alcoholic Steatohepatitis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-alcoholic Steatohepatitis.
The global Non-alcoholic Steatohepatitis market size is projected to grow from US$ 3115.9 million in 2022 to US$ 12070 million in 2029; it is expected to grow at a CAGR of 12070 from 2023 to 2029.
United States market for Non-alcoholic Steatohepatitis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Non-alcoholic Steatohepatitis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Non-alcoholic Steatohepatitis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Non-alcoholic Steatohepatitis players cover AstraZeneca, Arena Pharmaceuticals, GSK, Novo Nordisk, Roche, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals and Galectin Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-alcoholic Steatohepatitis market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Solid
- Liquid
- Oral
- Parenteral
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca
- Arena Pharmaceuticals
- GSK
- Novo Nordisk
- Roche
- Vivus
- Arisaph Pharmaceuticals
- Cempra Pharmaceuticals
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead
- Immuron
- Interceptpharma
- Raptor Pharmaceutical
- Takeda
- Tobira Therapeutics
- Verva
- Viking Therapeutics
What is the 10-year outlook for the global Non-alcoholic Steatohepatitis market?
What factors are driving Non-alcoholic Steatohepatitis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non-alcoholic Steatohepatitis market opportunities vary by end market size?
How does Non-alcoholic Steatohepatitis break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-alcoholic Steatohepatitis Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Non-alcoholic Steatohepatitis by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Non-alcoholic Steatohepatitis by Country/Region, 2018, 2022 & 2029
2.2 Non-alcoholic Steatohepatitis Segment by Type
2.2.1 Solid
2.2.2 Liquid
2.3 Non-alcoholic Steatohepatitis Sales by Type
2.3.1 Global Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
2.3.2 Global Non-alcoholic Steatohepatitis Revenue and Market Share by Type (2018-2023)
2.3.3 Global Non-alcoholic Steatohepatitis Sale Price by Type (2018-2023)
2.4 Non-alcoholic Steatohepatitis Segment by Application
2.4.1 Oral
2.4.2 Parenteral
2.5 Non-alcoholic Steatohepatitis Sales by Application
2.5.1 Global Non-alcoholic Steatohepatitis Sale Market Share by Application (2018-2023)
2.5.2 Global Non-alcoholic Steatohepatitis Revenue and Market Share by Application (2018-2023)
2.5.3 Global Non-alcoholic Steatohepatitis Sale Price by Application (2018-2023)
3 GLOBAL NON-ALCOHOLIC STEATOHEPATITIS BY COMPANY
3.1 Global Non-alcoholic Steatohepatitis Breakdown Data by Company
3.1.1 Global Non-alcoholic Steatohepatitis Annual Sales by Company (2018-2023)
3.1.2 Global Non-alcoholic Steatohepatitis Sales Market Share by Company (2018-2023)
3.2 Global Non-alcoholic Steatohepatitis Annual Revenue by Company (2018-2023)
3.2.1 Global Non-alcoholic Steatohepatitis Revenue by Company (2018-2023)
3.2.2 Global Non-alcoholic Steatohepatitis Revenue Market Share by Company (2018-2023)
3.3 Global Non-alcoholic Steatohepatitis Sale Price by Company
3.4 Key Manufacturers Non-alcoholic Steatohepatitis Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-alcoholic Steatohepatitis Product Location Distribution
3.4.2 Players Non-alcoholic Steatohepatitis Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NON-ALCOHOLIC STEATOHEPATITIS BY GEOGRAPHIC REGION
4.1 World Historic Non-alcoholic Steatohepatitis Market Size by Geographic Region (2018-2023)
4.1.1 Global Non-alcoholic Steatohepatitis Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Non-alcoholic Steatohepatitis Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Non-alcoholic Steatohepatitis Market Size by Country/Region (2018-2023)
4.2.1 Global Non-alcoholic Steatohepatitis Annual Sales by Country/Region (2018-2023)
4.2.2 Global Non-alcoholic Steatohepatitis Annual Revenue by Country/Region (2018-2023)
4.3 Americas Non-alcoholic Steatohepatitis Sales Growth
4.4 APAC Non-alcoholic Steatohepatitis Sales Growth
4.5 Europe Non-alcoholic Steatohepatitis Sales Growth
4.6 Middle East & Africa Non-alcoholic Steatohepatitis Sales Growth
5 AMERICAS
5.1 Americas Non-alcoholic Steatohepatitis Sales by Country
5.1.1 Americas Non-alcoholic Steatohepatitis Sales by Country (2018-2023)
5.1.2 Americas Non-alcoholic Steatohepatitis Revenue by Country (2018-2023)
5.2 Americas Non-alcoholic Steatohepatitis Sales by Type
5.3 Americas Non-alcoholic Steatohepatitis Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-alcoholic Steatohepatitis Sales by Region
6.1.1 APAC Non-alcoholic Steatohepatitis Sales by Region (2018-2023)
6.1.2 APAC Non-alcoholic Steatohepatitis Revenue by Region (2018-2023)
6.2 APAC Non-alcoholic Steatohepatitis Sales by Type
6.3 APAC Non-alcoholic Steatohepatitis Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-alcoholic Steatohepatitis by Country
7.1.1 Europe Non-alcoholic Steatohepatitis Sales by Country (2018-2023)
7.1.2 Europe Non-alcoholic Steatohepatitis Revenue by Country (2018-2023)
7.2 Europe Non-alcoholic Steatohepatitis Sales by Type
7.3 Europe Non-alcoholic Steatohepatitis Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-alcoholic Steatohepatitis by Country
8.1.1 Middle East & Africa Non-alcoholic Steatohepatitis Sales by Country (2018-2023)
8.1.2 Middle East & Africa Non-alcoholic Steatohepatitis Revenue by Country (2018-2023)
8.2 Middle East & Africa Non-alcoholic Steatohepatitis Sales by Type
8.3 Middle East & Africa Non-alcoholic Steatohepatitis Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-alcoholic Steatohepatitis
10.3 Manufacturing Process Analysis of Non-alcoholic Steatohepatitis
10.4 Industry Chain Structure of Non-alcoholic Steatohepatitis
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-alcoholic Steatohepatitis Distributors
11.3 Non-alcoholic Steatohepatitis Customer
12 WORLD FORECAST REVIEW FOR NON-ALCOHOLIC STEATOHEPATITIS BY GEOGRAPHIC REGION
12.1 Global Non-alcoholic Steatohepatitis Market Size Forecast by Region
12.1.1 Global Non-alcoholic Steatohepatitis Forecast by Region (2024-2029)
12.1.2 Global Non-alcoholic Steatohepatitis Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Non-alcoholic Steatohepatitis Forecast by Type
12.7 Global Non-alcoholic Steatohepatitis Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.1.3 AstraZeneca Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Arena Pharmaceuticals
13.2.1 Arena Pharmaceuticals Company Information
13.2.2 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.2.3 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Arena Pharmaceuticals Main Business Overview
13.2.5 Arena Pharmaceuticals Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.3.3 GSK Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Novo Nordisk
13.4.1 Novo Nordisk Company Information
13.4.2 Novo Nordisk Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novo Nordisk Main Business Overview
13.4.5 Novo Nordisk Latest Developments
13.5 Roche
13.5.1 Roche Company Information
13.5.2 Roche Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.5.3 Roche Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Roche Main Business Overview
13.5.5 Roche Latest Developments
13.6 Vivus
13.6.1 Vivus Company Information
13.6.2 Vivus Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.6.3 Vivus Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Vivus Main Business Overview
13.6.5 Vivus Latest Developments
13.7 Arisaph Pharmaceuticals
13.7.1 Arisaph Pharmaceuticals Company Information
13.7.2 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.7.3 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Arisaph Pharmaceuticals Main Business Overview
13.7.5 Arisaph Pharmaceuticals Latest Developments
13.8 Cempra Pharmaceuticals
13.8.1 Cempra Pharmaceuticals Company Information
13.8.2 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.8.3 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Cempra Pharmaceuticals Main Business Overview
13.8.5 Cempra Pharmaceuticals Latest Developments
13.9 Galectin Therapeutics
13.9.1 Galectin Therapeutics Company Information
13.9.2 Galectin Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.9.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Galectin Therapeutics Main Business Overview
13.9.5 Galectin Therapeutics Latest Developments
13.10 Galmed Pharmaceuticals
13.10.1 Galmed Pharmaceuticals Company Information
13.10.2 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.10.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Galmed Pharmaceuticals Main Business Overview
13.10.5 Galmed Pharmaceuticals Latest Developments
13.11 Genfit
13.11.1 Genfit Company Information
13.11.2 Genfit Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.11.3 Genfit Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Genfit Main Business Overview
13.11.5 Genfit Latest Developments
13.12 Gilead
13.12.1 Gilead Company Information
13.12.2 Gilead Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.12.3 Gilead Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Gilead Main Business Overview
13.12.5 Gilead Latest Developments
13.13 Immuron
13.13.1 Immuron Company Information
13.13.2 Immuron Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.13.3 Immuron Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Immuron Main Business Overview
13.13.5 Immuron Latest Developments
13.14 Interceptpharma
13.14.1 Interceptpharma Company Information
13.14.2 Interceptpharma Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.14.3 Interceptpharma Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Interceptpharma Main Business Overview
13.14.5 Interceptpharma Latest Developments
13.15 Raptor Pharmaceutical
13.15.1 Raptor Pharmaceutical Company Information
13.15.2 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.15.3 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Raptor Pharmaceutical Main Business Overview
13.15.5 Raptor Pharmaceutical Latest Developments
13.16 Takeda
13.16.1 Takeda Company Information
13.16.2 Takeda Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.16.3 Takeda Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Takeda Main Business Overview
13.16.5 Takeda Latest Developments
13.17 Tobira Therapeutics
13.17.1 Tobira Therapeutics Company Information
13.17.2 Tobira Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.17.3 Tobira Therapeutics Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Tobira Therapeutics Main Business Overview
13.17.5 Tobira Therapeutics Latest Developments
13.18 Verva
13.18.1 Verva Company Information
13.18.2 Verva Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.18.3 Verva Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Verva Main Business Overview
13.18.5 Verva Latest Developments
13.19 Viking Therapeutics
13.19.1 Viking Therapeutics Company Information
13.19.2 Viking Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.19.3 Viking Therapeutics Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Viking Therapeutics Main Business Overview
13.19.5 Viking Therapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-alcoholic Steatohepatitis Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Non-alcoholic Steatohepatitis by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Non-alcoholic Steatohepatitis by Country/Region, 2018, 2022 & 2029
2.2 Non-alcoholic Steatohepatitis Segment by Type
2.2.1 Solid
2.2.2 Liquid
2.3 Non-alcoholic Steatohepatitis Sales by Type
2.3.1 Global Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
2.3.2 Global Non-alcoholic Steatohepatitis Revenue and Market Share by Type (2018-2023)
2.3.3 Global Non-alcoholic Steatohepatitis Sale Price by Type (2018-2023)
2.4 Non-alcoholic Steatohepatitis Segment by Application
2.4.1 Oral
2.4.2 Parenteral
2.5 Non-alcoholic Steatohepatitis Sales by Application
2.5.1 Global Non-alcoholic Steatohepatitis Sale Market Share by Application (2018-2023)
2.5.2 Global Non-alcoholic Steatohepatitis Revenue and Market Share by Application (2018-2023)
2.5.3 Global Non-alcoholic Steatohepatitis Sale Price by Application (2018-2023)
3 GLOBAL NON-ALCOHOLIC STEATOHEPATITIS BY COMPANY
3.1 Global Non-alcoholic Steatohepatitis Breakdown Data by Company
3.1.1 Global Non-alcoholic Steatohepatitis Annual Sales by Company (2018-2023)
3.1.2 Global Non-alcoholic Steatohepatitis Sales Market Share by Company (2018-2023)
3.2 Global Non-alcoholic Steatohepatitis Annual Revenue by Company (2018-2023)
3.2.1 Global Non-alcoholic Steatohepatitis Revenue by Company (2018-2023)
3.2.2 Global Non-alcoholic Steatohepatitis Revenue Market Share by Company (2018-2023)
3.3 Global Non-alcoholic Steatohepatitis Sale Price by Company
3.4 Key Manufacturers Non-alcoholic Steatohepatitis Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-alcoholic Steatohepatitis Product Location Distribution
3.4.2 Players Non-alcoholic Steatohepatitis Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NON-ALCOHOLIC STEATOHEPATITIS BY GEOGRAPHIC REGION
4.1 World Historic Non-alcoholic Steatohepatitis Market Size by Geographic Region (2018-2023)
4.1.1 Global Non-alcoholic Steatohepatitis Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Non-alcoholic Steatohepatitis Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Non-alcoholic Steatohepatitis Market Size by Country/Region (2018-2023)
4.2.1 Global Non-alcoholic Steatohepatitis Annual Sales by Country/Region (2018-2023)
4.2.2 Global Non-alcoholic Steatohepatitis Annual Revenue by Country/Region (2018-2023)
4.3 Americas Non-alcoholic Steatohepatitis Sales Growth
4.4 APAC Non-alcoholic Steatohepatitis Sales Growth
4.5 Europe Non-alcoholic Steatohepatitis Sales Growth
4.6 Middle East & Africa Non-alcoholic Steatohepatitis Sales Growth
5 AMERICAS
5.1 Americas Non-alcoholic Steatohepatitis Sales by Country
5.1.1 Americas Non-alcoholic Steatohepatitis Sales by Country (2018-2023)
5.1.2 Americas Non-alcoholic Steatohepatitis Revenue by Country (2018-2023)
5.2 Americas Non-alcoholic Steatohepatitis Sales by Type
5.3 Americas Non-alcoholic Steatohepatitis Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-alcoholic Steatohepatitis Sales by Region
6.1.1 APAC Non-alcoholic Steatohepatitis Sales by Region (2018-2023)
6.1.2 APAC Non-alcoholic Steatohepatitis Revenue by Region (2018-2023)
6.2 APAC Non-alcoholic Steatohepatitis Sales by Type
6.3 APAC Non-alcoholic Steatohepatitis Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-alcoholic Steatohepatitis by Country
7.1.1 Europe Non-alcoholic Steatohepatitis Sales by Country (2018-2023)
7.1.2 Europe Non-alcoholic Steatohepatitis Revenue by Country (2018-2023)
7.2 Europe Non-alcoholic Steatohepatitis Sales by Type
7.3 Europe Non-alcoholic Steatohepatitis Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-alcoholic Steatohepatitis by Country
8.1.1 Middle East & Africa Non-alcoholic Steatohepatitis Sales by Country (2018-2023)
8.1.2 Middle East & Africa Non-alcoholic Steatohepatitis Revenue by Country (2018-2023)
8.2 Middle East & Africa Non-alcoholic Steatohepatitis Sales by Type
8.3 Middle East & Africa Non-alcoholic Steatohepatitis Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-alcoholic Steatohepatitis
10.3 Manufacturing Process Analysis of Non-alcoholic Steatohepatitis
10.4 Industry Chain Structure of Non-alcoholic Steatohepatitis
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-alcoholic Steatohepatitis Distributors
11.3 Non-alcoholic Steatohepatitis Customer
12 WORLD FORECAST REVIEW FOR NON-ALCOHOLIC STEATOHEPATITIS BY GEOGRAPHIC REGION
12.1 Global Non-alcoholic Steatohepatitis Market Size Forecast by Region
12.1.1 Global Non-alcoholic Steatohepatitis Forecast by Region (2024-2029)
12.1.2 Global Non-alcoholic Steatohepatitis Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Non-alcoholic Steatohepatitis Forecast by Type
12.7 Global Non-alcoholic Steatohepatitis Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.1.3 AstraZeneca Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Arena Pharmaceuticals
13.2.1 Arena Pharmaceuticals Company Information
13.2.2 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.2.3 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Arena Pharmaceuticals Main Business Overview
13.2.5 Arena Pharmaceuticals Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.3.3 GSK Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Novo Nordisk
13.4.1 Novo Nordisk Company Information
13.4.2 Novo Nordisk Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novo Nordisk Main Business Overview
13.4.5 Novo Nordisk Latest Developments
13.5 Roche
13.5.1 Roche Company Information
13.5.2 Roche Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.5.3 Roche Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Roche Main Business Overview
13.5.5 Roche Latest Developments
13.6 Vivus
13.6.1 Vivus Company Information
13.6.2 Vivus Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.6.3 Vivus Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Vivus Main Business Overview
13.6.5 Vivus Latest Developments
13.7 Arisaph Pharmaceuticals
13.7.1 Arisaph Pharmaceuticals Company Information
13.7.2 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.7.3 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Arisaph Pharmaceuticals Main Business Overview
13.7.5 Arisaph Pharmaceuticals Latest Developments
13.8 Cempra Pharmaceuticals
13.8.1 Cempra Pharmaceuticals Company Information
13.8.2 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.8.3 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Cempra Pharmaceuticals Main Business Overview
13.8.5 Cempra Pharmaceuticals Latest Developments
13.9 Galectin Therapeutics
13.9.1 Galectin Therapeutics Company Information
13.9.2 Galectin Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.9.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Galectin Therapeutics Main Business Overview
13.9.5 Galectin Therapeutics Latest Developments
13.10 Galmed Pharmaceuticals
13.10.1 Galmed Pharmaceuticals Company Information
13.10.2 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.10.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Galmed Pharmaceuticals Main Business Overview
13.10.5 Galmed Pharmaceuticals Latest Developments
13.11 Genfit
13.11.1 Genfit Company Information
13.11.2 Genfit Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.11.3 Genfit Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Genfit Main Business Overview
13.11.5 Genfit Latest Developments
13.12 Gilead
13.12.1 Gilead Company Information
13.12.2 Gilead Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.12.3 Gilead Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Gilead Main Business Overview
13.12.5 Gilead Latest Developments
13.13 Immuron
13.13.1 Immuron Company Information
13.13.2 Immuron Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.13.3 Immuron Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Immuron Main Business Overview
13.13.5 Immuron Latest Developments
13.14 Interceptpharma
13.14.1 Interceptpharma Company Information
13.14.2 Interceptpharma Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.14.3 Interceptpharma Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Interceptpharma Main Business Overview
13.14.5 Interceptpharma Latest Developments
13.15 Raptor Pharmaceutical
13.15.1 Raptor Pharmaceutical Company Information
13.15.2 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.15.3 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Raptor Pharmaceutical Main Business Overview
13.15.5 Raptor Pharmaceutical Latest Developments
13.16 Takeda
13.16.1 Takeda Company Information
13.16.2 Takeda Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.16.3 Takeda Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Takeda Main Business Overview
13.16.5 Takeda Latest Developments
13.17 Tobira Therapeutics
13.17.1 Tobira Therapeutics Company Information
13.17.2 Tobira Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.17.3 Tobira Therapeutics Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Tobira Therapeutics Main Business Overview
13.17.5 Tobira Therapeutics Latest Developments
13.18 Verva
13.18.1 Verva Company Information
13.18.2 Verva Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.18.3 Verva Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Verva Main Business Overview
13.18.5 Verva Latest Developments
13.19 Viking Therapeutics
13.19.1 Viking Therapeutics Company Information
13.19.2 Viking Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
13.19.3 Viking Therapeutics Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Viking Therapeutics Main Business Overview
13.19.5 Viking Therapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Non-alcoholic Steatohepatitis Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Non-alcoholic Steatohepatitis Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Solid
Table 4. Major Players of Liquid
Table 5. Global Non-alcoholic Steatohepatitis Sales by Type (2018-2023) & (MT)
Table 6. Global Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
Table 7. Global Non-alcoholic Steatohepatitis Revenue by Type (2018-2023) & ($ million)
Table 8. Global Non-alcoholic Steatohepatitis Revenue Market Share by Type (2018-2023)
Table 9. Global Non-alcoholic Steatohepatitis Sale Price by Type (2018-2023) & (USD/Kg)
Table 10. Global Non-alcoholic Steatohepatitis Sales by Application (2018-2023) & (MT)
Table 11. Global Non-alcoholic Steatohepatitis Sales Market Share by Application (2018-2023)
Table 12. Global Non-alcoholic Steatohepatitis Revenue by Application (2018-2023)
Table 13. Global Non-alcoholic Steatohepatitis Revenue Market Share by Application (2018-2023)
Table 14. Global Non-alcoholic Steatohepatitis Sale Price by Application (2018-2023) & (USD/Kg)
Table 15. Global Non-alcoholic Steatohepatitis Sales by Company (2018-2023) & (MT)
Table 16. Global Non-alcoholic Steatohepatitis Sales Market Share by Company (2018-2023)
Table 17. Global Non-alcoholic Steatohepatitis Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Non-alcoholic Steatohepatitis Revenue Market Share by Company (2018-2023)
Table 19. Global Non-alcoholic Steatohepatitis Sale Price by Company (2018-2023) & (USD/Kg)
Table 20. Key Manufacturers Non-alcoholic Steatohepatitis Producing Area Distribution and Sales Area
Table 21. Players Non-alcoholic Steatohepatitis Products Offered
Table 22. Non-alcoholic Steatohepatitis Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Non-alcoholic Steatohepatitis Sales by Geographic Region (2018-2023) & (MT)
Table 26. Global Non-alcoholic Steatohepatitis Sales Market Share Geographic Region (2018-2023)
Table 27. Global Non-alcoholic Steatohepatitis Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Non-alcoholic Steatohepatitis Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Non-alcoholic Steatohepatitis Sales by Country/Region (2018-2023) & (MT)
Table 30. Global Non-alcoholic Steatohepatitis Sales Market Share by Country/Region (2018-2023)
Table 31. Global Non-alcoholic Steatohepatitis Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Non-alcoholic Steatohepatitis Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Non-alcoholic Steatohepatitis Sales by Country (2018-2023) & (MT)
Table 34. Americas Non-alcoholic Steatohepatitis Sales Market Share by Country (2018-2023)
Table 35. Americas Non-alcoholic Steatohepatitis Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Non-alcoholic Steatohepatitis Revenue Market Share by Country (2018-2023)
Table 37. Americas Non-alcoholic Steatohepatitis Sales by Type (2018-2023) & (MT)
Table 38. Americas Non-alcoholic Steatohepatitis Sales by Application (2018-2023) & (MT)
Table 39. APAC Non-alcoholic Steatohepatitis Sales by Region (2018-2023) & (MT)
Table 40. APAC Non-alcoholic Steatohepatitis Sales Market Share by Region (2018-2023)
Table 41. APAC Non-alcoholic Steatohepatitis Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Non-alcoholic Steatohepatitis Revenue Market Share by Region (2018-2023)
Table 43. APAC Non-alcoholic Steatohepatitis Sales by Type (2018-2023) & (MT)
Table 44. APAC Non-alcoholic Steatohepatitis Sales by Application (2018-2023) & (MT)
Table 45. Europe Non-alcoholic Steatohepatitis Sales by Country (2018-2023) & (MT)
Table 46. Europe Non-alcoholic Steatohepatitis Sales Market Share by Country (2018-2023)
Table 47. Europe Non-alcoholic Steatohepatitis Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Non-alcoholic Steatohepatitis Revenue Market Share by Country (2018-2023)
Table 49. Europe Non-alcoholic Steatohepatitis Sales by Type (2018-2023) & (MT)
Table 50. Europe Non-alcoholic Steatohepatitis Sales by Application (2018-2023) & (MT)
Table 51. Middle East & Africa Non-alcoholic Steatohepatitis Sales by Country (2018-2023) & (MT)
Table 52. Middle East & Africa Non-alcoholic Steatohepatitis Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Non-alcoholic Steatohepatitis Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Non-alcoholic Steatohepatitis Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Non-alcoholic Steatohepatitis Sales by Type (2018-2023) & (MT)
Table 56. Middle East & Africa Non-alcoholic Steatohepatitis Sales by Application (2018-2023) & (MT)
Table 57. Key Market Drivers & Growth Opportunities of Non-alcoholic Steatohepatitis
Table 58. Key Market Challenges & Risks of Non-alcoholic Steatohepatitis
Table 59. Key Industry Trends of Non-alcoholic Steatohepatitis
Table 60. Non-alcoholic Steatohepatitis Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Non-alcoholic Steatohepatitis Distributors List
Table 63. Non-alcoholic Steatohepatitis Customer List
Table 64. Global Non-alcoholic Steatohepatitis Sales Forecast by Region (2024-2029) & (MT)
Table 65. Global Non-alcoholic Steatohepatitis Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Non-alcoholic Steatohepatitis Sales Forecast by Country (2024-2029) & (MT)
Table 67. Americas Non-alcoholic Steatohepatitis Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Non-alcoholic Steatohepatitis Sales Forecast by Region (2024-2029) & (MT)
Table 69. APAC Non-alcoholic Steatohepatitis Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Non-alcoholic Steatohepatitis Sales Forecast by Country (2024-2029) & (MT)
Table 71. Europe Non-alcoholic Steatohepatitis Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Non-alcoholic Steatohepatitis Sales Forecast by Country (2024-2029) & (MT)
Table 73. Middle East & Africa Non-alcoholic Steatohepatitis Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Non-alcoholic Steatohepatitis Sales Forecast by Type (2024-2029) & (MT)
Table 75. Global Non-alcoholic Steatohepatitis Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Non-alcoholic Steatohepatitis Sales Forecast by Application (2024-2029) & (MT)
Table 77. Global Non-alcoholic Steatohepatitis Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. AstraZeneca Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 79. AstraZeneca Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 80. AstraZeneca Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 81. AstraZeneca Main Business
Table 82. AstraZeneca Latest Developments
Table 83. Arena Pharmaceuticals Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 84. Arena Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 85. Arena Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 86. Arena Pharmaceuticals Main Business
Table 87. Arena Pharmaceuticals Latest Developments
Table 88. GSK Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 89. GSK Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 90. GSK Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 91. GSK Main Business
Table 92. GSK Latest Developments
Table 93. Novo Nordisk Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 94. Novo Nordisk Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 95. Novo Nordisk Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 96. Novo Nordisk Main Business
Table 97. Novo Nordisk Latest Developments
Table 98. Roche Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 99. Roche Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 100. Roche Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 101. Roche Main Business
Table 102. Roche Latest Developments
Table 103. Vivus Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 104. Vivus Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 105. Vivus Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 106. Vivus Main Business
Table 107. Vivus Latest Developments
Table 108. Arisaph Pharmaceuticals Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 109. Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 110. Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 111. Arisaph Pharmaceuticals Main Business
Table 112. Arisaph Pharmaceuticals Latest Developments
Table 113. Cempra Pharmaceuticals Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 114. Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 115. Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 116. Cempra Pharmaceuticals Main Business
Table 117. Cempra Pharmaceuticals Latest Developments
Table 118. Galectin Therapeutics Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 119. Galectin Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 120. Galectin Therapeutics Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 121. Galectin Therapeutics Main Business
Table 122. Galectin Therapeutics Latest Developments
Table 123. Galmed Pharmaceuticals Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 124. Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 125. Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 126. Galmed Pharmaceuticals Main Business
Table 127. Galmed Pharmaceuticals Latest Developments
Table 128. Genfit Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 129. Genfit Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 130. Genfit Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 131. Genfit Main Business
Table 132. Genfit Latest Developments
Table 133. Gilead Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 134. Gilead Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 135. Gilead Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 136. Gilead Main Business
Table 137. Gilead Latest Developments
Table 138. Immuron Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 139. Immuron Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 140. Immuron Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 141. Immuron Main Business
Table 142. Immuron Latest Developments
Table 143. Interceptpharma Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 144. Interceptpharma Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 145. Interceptpharma Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 146. Interceptpharma Main Business
Table 147. Interceptpharma Latest Developments
Table 148. Raptor Pharmaceutical Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 149. Raptor Pharmaceutical Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 150. Raptor Pharmaceutical Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 151. Raptor Pharmaceutical Main Business
Table 152. Raptor Pharmaceutical Latest Developments
Table 153. Takeda Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 154. Takeda Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 155. Takeda Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 156. Takeda Main Business
Table 157. Takeda Latest Developments
Table 158. Tobira Therapeutics Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 159. Tobira Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 160. Tobira Therapeutics Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 161. Tobira Therapeutics Main Business
Table 162. Tobira Therapeutics Latest Developments
Table 163. Verva Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 164. Verva Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 165. Verva Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 166. Verva Main Business
Table 167. Verva Latest Developments
Table 168. Viking Therapeutics Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 169. Viking Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 170. Viking Therapeutics Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 171. Viking Therapeutics Main Business
Table 172. Viking Therapeutics Latest Developments
Table 1. Non-alcoholic Steatohepatitis Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Non-alcoholic Steatohepatitis Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Solid
Table 4. Major Players of Liquid
Table 5. Global Non-alcoholic Steatohepatitis Sales by Type (2018-2023) & (MT)
Table 6. Global Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
Table 7. Global Non-alcoholic Steatohepatitis Revenue by Type (2018-2023) & ($ million)
Table 8. Global Non-alcoholic Steatohepatitis Revenue Market Share by Type (2018-2023)
Table 9. Global Non-alcoholic Steatohepatitis Sale Price by Type (2018-2023) & (USD/Kg)
Table 10. Global Non-alcoholic Steatohepatitis Sales by Application (2018-2023) & (MT)
Table 11. Global Non-alcoholic Steatohepatitis Sales Market Share by Application (2018-2023)
Table 12. Global Non-alcoholic Steatohepatitis Revenue by Application (2018-2023)
Table 13. Global Non-alcoholic Steatohepatitis Revenue Market Share by Application (2018-2023)
Table 14. Global Non-alcoholic Steatohepatitis Sale Price by Application (2018-2023) & (USD/Kg)
Table 15. Global Non-alcoholic Steatohepatitis Sales by Company (2018-2023) & (MT)
Table 16. Global Non-alcoholic Steatohepatitis Sales Market Share by Company (2018-2023)
Table 17. Global Non-alcoholic Steatohepatitis Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Non-alcoholic Steatohepatitis Revenue Market Share by Company (2018-2023)
Table 19. Global Non-alcoholic Steatohepatitis Sale Price by Company (2018-2023) & (USD/Kg)
Table 20. Key Manufacturers Non-alcoholic Steatohepatitis Producing Area Distribution and Sales Area
Table 21. Players Non-alcoholic Steatohepatitis Products Offered
Table 22. Non-alcoholic Steatohepatitis Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Non-alcoholic Steatohepatitis Sales by Geographic Region (2018-2023) & (MT)
Table 26. Global Non-alcoholic Steatohepatitis Sales Market Share Geographic Region (2018-2023)
Table 27. Global Non-alcoholic Steatohepatitis Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Non-alcoholic Steatohepatitis Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Non-alcoholic Steatohepatitis Sales by Country/Region (2018-2023) & (MT)
Table 30. Global Non-alcoholic Steatohepatitis Sales Market Share by Country/Region (2018-2023)
Table 31. Global Non-alcoholic Steatohepatitis Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Non-alcoholic Steatohepatitis Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Non-alcoholic Steatohepatitis Sales by Country (2018-2023) & (MT)
Table 34. Americas Non-alcoholic Steatohepatitis Sales Market Share by Country (2018-2023)
Table 35. Americas Non-alcoholic Steatohepatitis Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Non-alcoholic Steatohepatitis Revenue Market Share by Country (2018-2023)
Table 37. Americas Non-alcoholic Steatohepatitis Sales by Type (2018-2023) & (MT)
Table 38. Americas Non-alcoholic Steatohepatitis Sales by Application (2018-2023) & (MT)
Table 39. APAC Non-alcoholic Steatohepatitis Sales by Region (2018-2023) & (MT)
Table 40. APAC Non-alcoholic Steatohepatitis Sales Market Share by Region (2018-2023)
Table 41. APAC Non-alcoholic Steatohepatitis Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Non-alcoholic Steatohepatitis Revenue Market Share by Region (2018-2023)
Table 43. APAC Non-alcoholic Steatohepatitis Sales by Type (2018-2023) & (MT)
Table 44. APAC Non-alcoholic Steatohepatitis Sales by Application (2018-2023) & (MT)
Table 45. Europe Non-alcoholic Steatohepatitis Sales by Country (2018-2023) & (MT)
Table 46. Europe Non-alcoholic Steatohepatitis Sales Market Share by Country (2018-2023)
Table 47. Europe Non-alcoholic Steatohepatitis Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Non-alcoholic Steatohepatitis Revenue Market Share by Country (2018-2023)
Table 49. Europe Non-alcoholic Steatohepatitis Sales by Type (2018-2023) & (MT)
Table 50. Europe Non-alcoholic Steatohepatitis Sales by Application (2018-2023) & (MT)
Table 51. Middle East & Africa Non-alcoholic Steatohepatitis Sales by Country (2018-2023) & (MT)
Table 52. Middle East & Africa Non-alcoholic Steatohepatitis Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Non-alcoholic Steatohepatitis Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Non-alcoholic Steatohepatitis Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Non-alcoholic Steatohepatitis Sales by Type (2018-2023) & (MT)
Table 56. Middle East & Africa Non-alcoholic Steatohepatitis Sales by Application (2018-2023) & (MT)
Table 57. Key Market Drivers & Growth Opportunities of Non-alcoholic Steatohepatitis
Table 58. Key Market Challenges & Risks of Non-alcoholic Steatohepatitis
Table 59. Key Industry Trends of Non-alcoholic Steatohepatitis
Table 60. Non-alcoholic Steatohepatitis Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Non-alcoholic Steatohepatitis Distributors List
Table 63. Non-alcoholic Steatohepatitis Customer List
Table 64. Global Non-alcoholic Steatohepatitis Sales Forecast by Region (2024-2029) & (MT)
Table 65. Global Non-alcoholic Steatohepatitis Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Non-alcoholic Steatohepatitis Sales Forecast by Country (2024-2029) & (MT)
Table 67. Americas Non-alcoholic Steatohepatitis Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Non-alcoholic Steatohepatitis Sales Forecast by Region (2024-2029) & (MT)
Table 69. APAC Non-alcoholic Steatohepatitis Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Non-alcoholic Steatohepatitis Sales Forecast by Country (2024-2029) & (MT)
Table 71. Europe Non-alcoholic Steatohepatitis Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Non-alcoholic Steatohepatitis Sales Forecast by Country (2024-2029) & (MT)
Table 73. Middle East & Africa Non-alcoholic Steatohepatitis Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Non-alcoholic Steatohepatitis Sales Forecast by Type (2024-2029) & (MT)
Table 75. Global Non-alcoholic Steatohepatitis Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Non-alcoholic Steatohepatitis Sales Forecast by Application (2024-2029) & (MT)
Table 77. Global Non-alcoholic Steatohepatitis Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. AstraZeneca Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 79. AstraZeneca Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 80. AstraZeneca Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 81. AstraZeneca Main Business
Table 82. AstraZeneca Latest Developments
Table 83. Arena Pharmaceuticals Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 84. Arena Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 85. Arena Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 86. Arena Pharmaceuticals Main Business
Table 87. Arena Pharmaceuticals Latest Developments
Table 88. GSK Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 89. GSK Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 90. GSK Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 91. GSK Main Business
Table 92. GSK Latest Developments
Table 93. Novo Nordisk Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 94. Novo Nordisk Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 95. Novo Nordisk Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 96. Novo Nordisk Main Business
Table 97. Novo Nordisk Latest Developments
Table 98. Roche Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 99. Roche Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 100. Roche Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 101. Roche Main Business
Table 102. Roche Latest Developments
Table 103. Vivus Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 104. Vivus Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 105. Vivus Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 106. Vivus Main Business
Table 107. Vivus Latest Developments
Table 108. Arisaph Pharmaceuticals Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 109. Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 110. Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 111. Arisaph Pharmaceuticals Main Business
Table 112. Arisaph Pharmaceuticals Latest Developments
Table 113. Cempra Pharmaceuticals Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 114. Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 115. Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 116. Cempra Pharmaceuticals Main Business
Table 117. Cempra Pharmaceuticals Latest Developments
Table 118. Galectin Therapeutics Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 119. Galectin Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 120. Galectin Therapeutics Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 121. Galectin Therapeutics Main Business
Table 122. Galectin Therapeutics Latest Developments
Table 123. Galmed Pharmaceuticals Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 124. Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 125. Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 126. Galmed Pharmaceuticals Main Business
Table 127. Galmed Pharmaceuticals Latest Developments
Table 128. Genfit Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 129. Genfit Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 130. Genfit Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 131. Genfit Main Business
Table 132. Genfit Latest Developments
Table 133. Gilead Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 134. Gilead Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 135. Gilead Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 136. Gilead Main Business
Table 137. Gilead Latest Developments
Table 138. Immuron Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 139. Immuron Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 140. Immuron Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 141. Immuron Main Business
Table 142. Immuron Latest Developments
Table 143. Interceptpharma Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 144. Interceptpharma Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 145. Interceptpharma Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 146. Interceptpharma Main Business
Table 147. Interceptpharma Latest Developments
Table 148. Raptor Pharmaceutical Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 149. Raptor Pharmaceutical Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 150. Raptor Pharmaceutical Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 151. Raptor Pharmaceutical Main Business
Table 152. Raptor Pharmaceutical Latest Developments
Table 153. Takeda Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 154. Takeda Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 155. Takeda Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 156. Takeda Main Business
Table 157. Takeda Latest Developments
Table 158. Tobira Therapeutics Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 159. Tobira Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 160. Tobira Therapeutics Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 161. Tobira Therapeutics Main Business
Table 162. Tobira Therapeutics Latest Developments
Table 163. Verva Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 164. Verva Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 165. Verva Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 166. Verva Main Business
Table 167. Verva Latest Developments
Table 168. Viking Therapeutics Basic Information, Non-alcoholic Steatohepatitis Manufacturing Base, Sales Area and Its Competitors
Table 169. Viking Therapeutics Non-alcoholic Steatohepatitis Product Portfolios and Specifications
Table 170. Viking Therapeutics Non-alcoholic Steatohepatitis Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2018-2023)
Table 171. Viking Therapeutics Main Business
Table 172. Viking Therapeutics Latest Developments
LIST OF FIGURES
Figure 1. Picture of Non-alcoholic Steatohepatitis
Figure 2. Non-alcoholic Steatohepatitis Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-alcoholic Steatohepatitis Sales Growth Rate 2018-2029 (MT)
Figure 7. Global Non-alcoholic Steatohepatitis Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Non-alcoholic Steatohepatitis Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Solid
Figure 10. Product Picture of Liquid
Figure 11. Global Non-alcoholic Steatohepatitis Sales Market Share by Type in 2022
Figure 12. Global Non-alcoholic Steatohepatitis Revenue Market Share by Type (2018-2023)
Figure 13. Non-alcoholic Steatohepatitis Consumed in Oral
Figure 14. Global Non-alcoholic Steatohepatitis Market: Oral (2018-2023) & (MT)
Figure 15. Non-alcoholic Steatohepatitis Consumed in Parenteral
Figure 16. Global Non-alcoholic Steatohepatitis Market: Parenteral (2018-2023) & (MT)
Figure 17. Global Non-alcoholic Steatohepatitis Sales Market Share by Application (2022)
Figure 18. Global Non-alcoholic Steatohepatitis Revenue Market Share by Application in 2022
Figure 19. Non-alcoholic Steatohepatitis Sales Market by Company in 2022 (MT)
Figure 20. Global Non-alcoholic Steatohepatitis Sales Market Share by Company in 2022
Figure 21. Non-alcoholic Steatohepatitis Revenue Market by Company in 2022 ($ Million)
Figure 22. Global Non-alcoholic Steatohepatitis Revenue Market Share by Company in 2022
Figure 23. Global Non-alcoholic Steatohepatitis Sales Market Share by Geographic Region (2018-2023)
Figure 24. Global Non-alcoholic Steatohepatitis Revenue Market Share by Geographic Region in 2022
Figure 25. Americas Non-alcoholic Steatohepatitis Sales 2018-2023 (MT)
Figure 26. Americas Non-alcoholic Steatohepatitis Revenue 2018-2023 ($ Millions)
Figure 27. APAC Non-alcoholic Steatohepatitis Sales 2018-2023 (MT)
Figure 28. APAC Non-alcoholic Steatohepatitis Revenue 2018-2023 ($ Millions)
Figure 29. Europe Non-alcoholic Steatohepatitis Sales 2018-2023 (MT)
Figure 30. Europe Non-alcoholic Steatohepatitis Revenue 2018-2023 ($ Millions)
Figure 31. Middle East & Africa Non-alcoholic Steatohepatitis Sales 2018-2023 (MT)
Figure 32. Middle East & Africa Non-alcoholic Steatohepatitis Revenue 2018-2023 ($ Millions)
Figure 33. Americas Non-alcoholic Steatohepatitis Sales Market Share by Country in 2022
Figure 34. Americas Non-alcoholic Steatohepatitis Revenue Market Share by Country in 2022
Figure 35. Americas Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
Figure 36. Americas Non-alcoholic Steatohepatitis Sales Market Share by Application (2018-2023)
Figure 37. United States Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 38. Canada Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 39. Mexico Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 40. Brazil Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 41. APAC Non-alcoholic Steatohepatitis Sales Market Share by Region in 2022
Figure 42. APAC Non-alcoholic Steatohepatitis Revenue Market Share by Regions in 2022
Figure 43. APAC Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
Figure 44. APAC Non-alcoholic Steatohepatitis Sales Market Share by Application (2018-2023)
Figure 45. China Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 46. Japan Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 47. South Korea Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 48. Southeast Asia Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 49. India Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 50. Australia Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 51. China Taiwan Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 52. Europe Non-alcoholic Steatohepatitis Sales Market Share by Country in 2022
Figure 53. Europe Non-alcoholic Steatohepatitis Revenue Market Share by Country in 2022
Figure 54. Europe Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
Figure 55. Europe Non-alcoholic Steatohepatitis Sales Market Share by Application (2018-2023)
Figure 56. Germany Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 57. France Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 58. UK Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 59. Italy Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 60. Russia Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 61. Middle East & Africa Non-alcoholic Steatohepatitis Sales Market Share by Country in 2022
Figure 62. Middle East & Africa Non-alcoholic Steatohepatitis Revenue Market Share by Country in 2022
Figure 63. Middle East & Africa Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
Figure 64. Middle East & Africa Non-alcoholic Steatohepatitis Sales Market Share by Application (2018-2023)
Figure 65. Egypt Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 66. South Africa Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 67. Israel Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 68. Turkey Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 69. GCC Country Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Non-alcoholic Steatohepatitis in 2022
Figure 71. Manufacturing Process Analysis of Non-alcoholic Steatohepatitis
Figure 72. Industry Chain Structure of Non-alcoholic Steatohepatitis
Figure 73. Channels of Distribution
Figure 74. Global Non-alcoholic Steatohepatitis Sales Market Forecast by Region (2024-2029)
Figure 75. Global Non-alcoholic Steatohepatitis Revenue Market Share Forecast by Region (2024-2029)
Figure 76. Global Non-alcoholic Steatohepatitis Sales Market Share Forecast by Type (2024-2029)
Figure 77. Global Non-alcoholic Steatohepatitis Revenue Market Share Forecast by Type (2024-2029)
Figure 78. Global Non-alcoholic Steatohepatitis Sales Market Share Forecast by Application (2024-2029)
Figure 79. Global Non-alcoholic Steatohepatitis Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Non-alcoholic Steatohepatitis
Figure 2. Non-alcoholic Steatohepatitis Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-alcoholic Steatohepatitis Sales Growth Rate 2018-2029 (MT)
Figure 7. Global Non-alcoholic Steatohepatitis Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Non-alcoholic Steatohepatitis Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Solid
Figure 10. Product Picture of Liquid
Figure 11. Global Non-alcoholic Steatohepatitis Sales Market Share by Type in 2022
Figure 12. Global Non-alcoholic Steatohepatitis Revenue Market Share by Type (2018-2023)
Figure 13. Non-alcoholic Steatohepatitis Consumed in Oral
Figure 14. Global Non-alcoholic Steatohepatitis Market: Oral (2018-2023) & (MT)
Figure 15. Non-alcoholic Steatohepatitis Consumed in Parenteral
Figure 16. Global Non-alcoholic Steatohepatitis Market: Parenteral (2018-2023) & (MT)
Figure 17. Global Non-alcoholic Steatohepatitis Sales Market Share by Application (2022)
Figure 18. Global Non-alcoholic Steatohepatitis Revenue Market Share by Application in 2022
Figure 19. Non-alcoholic Steatohepatitis Sales Market by Company in 2022 (MT)
Figure 20. Global Non-alcoholic Steatohepatitis Sales Market Share by Company in 2022
Figure 21. Non-alcoholic Steatohepatitis Revenue Market by Company in 2022 ($ Million)
Figure 22. Global Non-alcoholic Steatohepatitis Revenue Market Share by Company in 2022
Figure 23. Global Non-alcoholic Steatohepatitis Sales Market Share by Geographic Region (2018-2023)
Figure 24. Global Non-alcoholic Steatohepatitis Revenue Market Share by Geographic Region in 2022
Figure 25. Americas Non-alcoholic Steatohepatitis Sales 2018-2023 (MT)
Figure 26. Americas Non-alcoholic Steatohepatitis Revenue 2018-2023 ($ Millions)
Figure 27. APAC Non-alcoholic Steatohepatitis Sales 2018-2023 (MT)
Figure 28. APAC Non-alcoholic Steatohepatitis Revenue 2018-2023 ($ Millions)
Figure 29. Europe Non-alcoholic Steatohepatitis Sales 2018-2023 (MT)
Figure 30. Europe Non-alcoholic Steatohepatitis Revenue 2018-2023 ($ Millions)
Figure 31. Middle East & Africa Non-alcoholic Steatohepatitis Sales 2018-2023 (MT)
Figure 32. Middle East & Africa Non-alcoholic Steatohepatitis Revenue 2018-2023 ($ Millions)
Figure 33. Americas Non-alcoholic Steatohepatitis Sales Market Share by Country in 2022
Figure 34. Americas Non-alcoholic Steatohepatitis Revenue Market Share by Country in 2022
Figure 35. Americas Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
Figure 36. Americas Non-alcoholic Steatohepatitis Sales Market Share by Application (2018-2023)
Figure 37. United States Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 38. Canada Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 39. Mexico Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 40. Brazil Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 41. APAC Non-alcoholic Steatohepatitis Sales Market Share by Region in 2022
Figure 42. APAC Non-alcoholic Steatohepatitis Revenue Market Share by Regions in 2022
Figure 43. APAC Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
Figure 44. APAC Non-alcoholic Steatohepatitis Sales Market Share by Application (2018-2023)
Figure 45. China Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 46. Japan Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 47. South Korea Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 48. Southeast Asia Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 49. India Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 50. Australia Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 51. China Taiwan Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 52. Europe Non-alcoholic Steatohepatitis Sales Market Share by Country in 2022
Figure 53. Europe Non-alcoholic Steatohepatitis Revenue Market Share by Country in 2022
Figure 54. Europe Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
Figure 55. Europe Non-alcoholic Steatohepatitis Sales Market Share by Application (2018-2023)
Figure 56. Germany Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 57. France Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 58. UK Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 59. Italy Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 60. Russia Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 61. Middle East & Africa Non-alcoholic Steatohepatitis Sales Market Share by Country in 2022
Figure 62. Middle East & Africa Non-alcoholic Steatohepatitis Revenue Market Share by Country in 2022
Figure 63. Middle East & Africa Non-alcoholic Steatohepatitis Sales Market Share by Type (2018-2023)
Figure 64. Middle East & Africa Non-alcoholic Steatohepatitis Sales Market Share by Application (2018-2023)
Figure 65. Egypt Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 66. South Africa Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 67. Israel Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 68. Turkey Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 69. GCC Country Non-alcoholic Steatohepatitis Revenue Growth 2018-2023 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Non-alcoholic Steatohepatitis in 2022
Figure 71. Manufacturing Process Analysis of Non-alcoholic Steatohepatitis
Figure 72. Industry Chain Structure of Non-alcoholic Steatohepatitis
Figure 73. Channels of Distribution
Figure 74. Global Non-alcoholic Steatohepatitis Sales Market Forecast by Region (2024-2029)
Figure 75. Global Non-alcoholic Steatohepatitis Revenue Market Share Forecast by Region (2024-2029)
Figure 76. Global Non-alcoholic Steatohepatitis Sales Market Share Forecast by Type (2024-2029)
Figure 77. Global Non-alcoholic Steatohepatitis Revenue Market Share Forecast by Type (2024-2029)
Figure 78. Global Non-alcoholic Steatohepatitis Sales Market Share Forecast by Application (2024-2029)
Figure 79. Global Non-alcoholic Steatohepatitis Revenue Market Share Forecast by Application (2024-2029)
